Davide Pastorelli

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo et al. · The Lancet Oncology · 2015 · 845 citations · Full text

Medicine, Oncology, Pharmacology +9

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Lorenza Rimassa, Eric Assénat, Markus Peck‐Radosavljevic et al. · The Lancet Oncology · 2018 · 349 citations

Medicine, Oncology, Pharmacology +11

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)

Matti Aapro, Alex Molassiotis, Mario Dicato et al. · Annals of Oncology · 2012 · 308 citations · Full text

Medicine, Oncology, Pharmacology +14

Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial

Davide Pastorelli, Aline S.C. Fabricio, Petros Giovanis et al. · Pharmacological Research · 2018 · 146 citations · Full text

Medicine, Oncology, Pharmacology +8

Use of Sorafenib in Patients With Hepatocellular Carcinoma Before Liver Transplantation: A Cost-Benefit Analysis While Awaiting Data on Sorafenib Safety

Alessandro Vitale, Michael L. Volk, Davide Pastorelli et al. · Hepatology · 2009 · 105 citations · Full text

Medicine, Oncology, Pharmacoeconomics +14